求助文献1篇

jiays

6 i9 m" {0 ?) L3 Q
J Clin Oncol. 2013 May 10;31(14):1732-9. doi: 10.1200/JCO.2012.45.2490. Epub 2013 Apr 8.
: R# @- u; {9 K6 {Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-linechemotherapy: KCSG-BR07-02.
- c3 Q) m) Q$ T7 l: F' x, @  wPark YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh do Y, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Ahn JS, Im YH.2 x& _& S2 A- r5 G( o
Source
9 O7 t7 F+ t; g$ ]7 G' m4 ]2 q, ?2 W( A
Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, Seoul, Korea.
1 Z# Y+ I4 D  e" Y% o7 w0 U' k* x! ~0 @0 Z
Abstract
! k6 o/ C- v2 o- i4 APURPOSE:
" m' @% g% L0 v8 U, k* E3 p% |The primary purpose of our study was to evaluate whether maintenance chemotherapy with paclitaxel/gemcitabine (PG) was superior to observation in improving progression-free survival (PFS) in patients with metastatic breast cancer (MBC) who achieved disease control with an initial six cycles of PG as their first-line treatment.7 n: z0 c* x  f1 `; H# @) I8 j

! ^+ ^. y$ Q% s& `, {- oPATIENTS AND METHODS:
4 x: M2 r* _0 |5 h; K, I# R+ uThe study was a prospective, randomized, multicenter, phase III trial. Patients MBC with who achieved disease control after six cycles of PG chemotherapy were randomly assigned to maintenance chemotherapy or observation until progression.
; C0 r# K. H! B+ C" d% X! Y
' c9 J9 a- N% q! RRESULTS:0 v5 [" b* n3 U. ~! G
Of 324 patients from 10 centers enrolled, 231 patients with MBC exhibited disease control (complete response + partial response + stable disease) with first-line PG and were randomly assigned to maintenance chemotherapy (n = 116) or observation (n = 115). The median age was 48 years (range, 28 to 76 years), median follow-up was 33 months, and median number of chemotherapy cycles in the maintenance group after random assignment was six. The median PFS time after random assignment was longer in the maintenance group than in the observation group (7.5 v 3.8 months, respectively; P = .026). The median overall survival (OS) time was longer in the maintenance group than in the observation group (32.3 v 23.5 months, respectively; P = .047). The rate of grade 3 or higher neutropenia after random assignment was higher in the maintenance group than in the observation group (61% v 0.9%, respectively; P < .001).
7 C, n9 o% ?2 R- h* Y. }- y) y6 r" m. L3 g2 W
CONCLUSION:
! G1 e# R6 q+ `  J8 aIn patients with MBC who achieved disease control with an initial six cycles of PG chemotherapy, maintenance PG chemotherapyresulted in better PFS and OS compared with observation.
/ T- g# e# f9 \* x  W9 I
5 l% R7 ?' l1 Z4 PComment in
3 V7 A8 d( C$ A" W1 d! q. V' s·                                 The search for an elusive uniform strategy for a heterogeneous disease: lesson learned? [J Clin Oncol. 2013]

20111109

下次求助贴上网址哦 亲